Skip to main content
SpringerLink
Log in

JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

JAK2V617F, a gain-of-function mutation in the tyrosine kinase JAK2, is frequently detected in classical myeloproliferative neoplasms (MPNs). In the present study, we determined the JAK2V617F allele burden in Japanese MPN patients using alternately binding probe competitive-polymerase chain reaction, a highly quantitative method recently developed by our group. Although we observed strong similarities in terms of epidemiological parameters associated with the JAK2V617F allele burden between our cohort and others, we found a higher JAK2V617F allele burden in Japanese polycythemia vera (PV) patients and lower frequencies of thrombosis in Japanese MPN patients compared with previous reports. In addition, despite the presence of high red blood cell counts, some patients bearing the JAK2V617F mutation were not diagnosed as PV, as their hemoglobin values were lower than the WHO PV criterion. In these patients, the JAK2V617F allele burden was strikingly similar to that in PV patients fulfilling the 2008 WHO criteria, suggesting that these patients can be classified as PV. Although isotopic measurement of red cell mass (RCM) is required for definitive diagnosis of PV, our data suggest that precise measurement of the JAK2V617F allele burden may improve the diagnosis of PV when RCM has not been determined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24:1128–38.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Milosevic JD, Kralovics R. Genetic and epigenetic alterations of myeloproliferative disorders. Int J Hematol. 2013;97:183–97.

    Article  CAS  PubMed  Google Scholar 

  3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.

    Article  CAS  PubMed  Google Scholar 

  4. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.

    Article  CAS  PubMed  Google Scholar 

  5. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.

    Article  CAS  PubMed  Google Scholar 

  6. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.

    Article  CAS  PubMed  Google Scholar 

  7. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162–8.

    Article  CAS  PubMed  Google Scholar 

  8. Vizmanos JL, Ormazabal C, Larrayoz MJ, Cross NC, Calasanz MJ. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. Leukemia. 2006;20:534–5.

    Article  CAS  PubMed  Google Scholar 

  9. Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis—impact on disease phenotype. Eur J Haematol. 2007;79:508–15.

    Article  CAS  PubMed  Google Scholar 

  10. Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlue J, et al. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol. 2009;37:1186–93.

    Article  CAS  PubMed  Google Scholar 

  11. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115:3589–97.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Xing S, Wanting TH, Zhao W, Ma J, Wang S, Xu X, et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008;111:5109–17.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K, et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia. 2008;22:87–95.

    Article  CAS  PubMed  Google Scholar 

  14. Marty C, Lacout C, Martin A, Hasan S, Jacquot S, Birling MC, et al. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood. 2010;116:783–7.

    Article  CAS  PubMed  Google Scholar 

  15. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111:3931–40.

    Article  CAS  PubMed  Google Scholar 

  16. Li J, Spensberger D, Ahn JS, Anand S, Beer PA, Ghevaert C, et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood. 2010;116:1528–38.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelotibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–7.

    Article  CAS  PubMed  Google Scholar 

  18. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945–53.

    Article  CAS  PubMed  Google Scholar 

  19. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007;21:1952–9.

    Article  CAS  PubMed  Google Scholar 

  20. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22:1299–307.

    Article  CAS  PubMed  Google Scholar 

  21. Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, et al. Influence of JAK2(V617F) allele burden on phenotype in essential thrombocythemia. Haematologica. 2008;93:41–8.

    Article  CAS  PubMed  Google Scholar 

  22. Carobbio A, Finazzi G, Antonioli E, Guglielmelli P, Vannucchi AM, Dellacasa CM, et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol. 2009;37:1016–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24:1574–9.

    Article  CAS  PubMed  Google Scholar 

  24. Silver RT, Vandris K, Wang YL, Adriano F, Jones AV, Christos PJ, et al. JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res. 2011;35:177–82.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood. 2009;114:1477–83.

    Article  CAS  PubMed  Google Scholar 

  26. Ha JS, Kim YK, Jung SI, Jung HR, Chung IS. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms. Ann Lab Med. 2012;32:385–91.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Zhou J, Ye YX, Zeng SG, Zhou Y, Mao ZG, Song XB, et al. Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts. PLoS One. 2013;8:e57856.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Park SH, Chi HS, Cho YU, Jang S, Park CJ. The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasm. Blood Res. 2013;48:128–32.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Morishita S, Komatsu N, Kirito K, Koda AH, Sekiguchi Y, Tsuneda S, et al. Alternately binding probe competitive PCR as a simple, cost-effective, and accurate quantification method for JAK2V617F allele burden in myeloproliferative neoplasms. Leuk Res. 2011;35:1632–6.

    Article  CAS  PubMed  Google Scholar 

  30. Rapado I, Albizua E, Ayala R, Hernandez JA, Garcia-Alonso L, Grande S, et al. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. Ann Hematol. 2008;87:741–9.

    Article  CAS  PubMed  Google Scholar 

  31. Dan K, Yamada T, Kimura Y, Usui N, Okamoto S, Sugihara T, et al. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group. Int J Hematol. 2006;83:443–9.

    Article  PubMed  Google Scholar 

  32. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105:2664–70.

    Article  CAS  PubMed  Google Scholar 

  33. Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer. 2007;109:2279–84.

    Article  PubMed  Google Scholar 

  34. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007;33:313–20.

    Article  CAS  PubMed  Google Scholar 

  35. Gorog DA, Yamamoto J, Saraf S, Ishii H, Ijiri Y, Ikarugi H, et al. First direct comparison of platelet reactivity and thrombolytic status between Japanese and Western volunteers: possible relationship to the “Japanese paradox”. Int J Cardiol. 2011;152:43–8.

    Article  PubMed  Google Scholar 

  36. Scott LM. The JAK2 exon 12 mutations: a comprehensive review. Am J Hematol. 2011;86:668–76.

    Article  CAS  PubMed  Google Scholar 

  37. Schnittger S, Bacher U, Haferlach C, Geer T, Muller P, Mittermuller J, et al. Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera. Haematologica. 2009;94:414–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  38. Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood. 2006;108:3913–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006;108:1865–7.

    Article  CAS  PubMed  Google Scholar 

  40. Okoli S, Harrison C. Emerging treatments for essential thrombocythemia. J Blood Med. 2011;2:151–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  41. Briere JB. Essential thrombocythemia. Orphanet J Rare Dis. 2007;2:3.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Barbui T, Thiele J, Carobbio A, Gisslinger H, Finazzi G, Rumi E, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol. 2014;89(2):199–202.

    Article  CAS  PubMed  Google Scholar 

  43. Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol. 2005;129:701–5.

    Article  CAS  PubMed  Google Scholar 

  44. Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood. 2013;122:1881–6.

    Article  CAS  PubMed  Google Scholar 

  45. Alvarez-Larran A, Ancochea A, Angona A, Pedro C, Garcia-Pallarols F, Martinez-Aviles L, et al. Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica. 2012;97:1704–7.

    Article  PubMed Central  PubMed  Google Scholar 

  46. McMullin MF, Reilly JT, Campbell P, Bareford D, Green AR, Harrison CN, et al. Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. Br J Haematol. 2007;138:821–2.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Kazuhiko Ikeda (Fukushima Medical University), Nobuyoshi Hanaoka (Wakayama Medical University), Toshiro Kurokawa (Toyama Red Cross Hospital), Hideo Harigae (Tohoku University), Takayuki Ikezoe (Kochi University), Jun Murakami (University of Toyama), Kensuke Usuki (NTT Kanto Medical Center), and Takao Hirano (Juntendo Nerima Hospital) for providing patient specimens and clinical information. We also thank Masaki Kobayashi and Ei Leen Liew for technical assistance and fruitful discussions; Yuki Kagawa for advice on statistics; Kyoko Kubo, Kazuko Kawamura, and Megumi Hasegawa for secretarial assistance; and other members of the Department of Hematology for support in this study. We also acknowledge the Laboratory of Molecular and Biochemical Research, Research Support Center, Juntendo University Graduate School of Medicine. This work was funded in part by JSPS (http://www.jsps.go.jp/english/e-grants/) KAKENHI Grant #25860416 (SM). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflict of interest

The authors declare no competing interests.

Author information

Authors and Affiliations

  1. Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan

    Yoko Edahiro, Kochi Takahashi, Yumi Hironaka, Yuriko Yahata, Yoshitaka Sunami, Shuichi Shirane, Miyuki Tsutsui & Norio Komatsu

  2. Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan

    Soji Morishita, Akimichi Ohsaka & Marito Araki

  3. Department of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan

    Kochi Takahashi & Satoshi Tsuneda

  4. Department of Hematology, Juntendo Urayasu Hospital, Chiba, Japan

    Masaaki Noguchi

  5. Department of Hematology, Juntendo Shizuoka Hospital, Shizuoka, Japan

    Michiaki Koike

  6. Department of Hematology, Sapporo Hokuyu Hospital, Hokkaido, Japan

    Kiyotoshi Imai

  7. Department of Hematology and Oncology, Yamanashi University, Yamanashi, Japan

    Keita Kirito

  8. Bio-Measurement Research Group, Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Ibaraki, Japan

    Naohiro Noda & Yuji Sekiguchi

Authors
  1. Yoko Edahiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Soji Morishita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kochi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yumi Hironaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuriko Yahata
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshitaka Sunami
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shuichi Shirane
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Miyuki Tsutsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masaaki Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Michiaki Koike
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kiyotoshi Imai
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Keita Kirito
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Naohiro Noda
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yuji Sekiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Satoshi Tsuneda
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Akimichi Ohsaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Marito Araki
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Norio Komatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Norio Komatsu.

About this article

Cite this article

Edahiro, Y., Morishita, S., Takahashi, K. et al. JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. Int J Hematol 99, 625–634 (2014). https://doi.org/10.1007/s12185-014-1567-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-014-1567-1

Keywords

Search

Navigation